New cancer drug FID-022 enters first human safety trial
Disease control
Recruiting now
This early-stage study tests a new drug called FID-022 in about 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and identify any side effects. Participants will receive the drug and be closely monitored for…
Phase: PHASE1 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated May 17, 2026 05:32 UTC